Kailera Therapeutics Inc.
KLRA | NASDAQ
$12.92
+$0.06 (+0.47%)
Nov 2, 2026, 10:06 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 |
|---|---|---|
Revenue | n/a | n/a |
Cost of Revenue | n/a | n/a |
Gross Profit | n/a | n/a |
Operating Income | -206.03M | -84.66M |
Interest Income | 15.71M | 5.72M |
Pretax Income | -190.17M | -78.87M |
Net Income | -190.17M | -78.87M |
Selling & General & Admin | 34.1M | 13.79M |
Research & Development | 171.93M | 70.87M |
Other Expenses | n/a | n/a |
Operating Expenses | 206.03M | 84.66M |
Interest Expense | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a |
Cost & Expenses | 206.03M | 84.66M |
Income Tax Expense | n/a | n/a |
Shares Outstanding (Basic) | 102.23M | 117.95M |
Shares Outstanding (Diluted) | 102.23M | 117.95M |
EPS (Basic) | -1.76 | -0.67 |
EPS (Diluted) | -1.76 | -0.67 |
EBITDA | -195.87M | -84.56M |
EBIT | -195.97M | -84.66M |
Depreciation & Amortization | 101K | 101K |
Add to Watchlist
Select watchlists to add or remove KLRA